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Tbjectives: The proinflammatory marker C-reactive protein has been demonstrated to
lay a role in the development of atherosclerosis. Endothelin-1 and nitric oxide ho-
eostasis is crucial for normal vasomotor function, limiting inflammatory activation and
aintaining a nonthrombogenic endothelial surface. In addition to its vasoactive prop-
rties, endothelin-1 is also an inflammatory cytokine. We have previously demonstrated
hat C-reactive protein impairs endothelial cell nitric oxide production. Protein kinase C,
n important signal transducer within the cell, is involved in several cellular responses
o external stimuli. We therefore sought to determine whether endothelin-1 exposure
odulates C-reactive protein’s effects on nitric oxide production via protein kinase C.
ethods: Endothelial cells were incubated with C-reactive protein (200 g),
ndothelin-1 (100 nM), C-reactive protein  endothelin-1, or phosphate-buffered
aline solution (control) for 24 hours. After exposure, endothelial nitric oxide
ynthase expression was determined in addition to total nitric oxide production and
rotein kinase C translocation and activity.
esults: Endothelial nitric oxide synthase protein expression was reduced following
ncubation with C-reactive protein and endothelin-1 treatment compared with base-
ine by 40% and 45%, respectively (P  .04); however, no additive effects were
een with coincubation. C-reactive protein produced a 47% decrease in nitric oxide
roduction compared with control. Coincubation with endothelin-1 resulted in a
ynergistic 70% reduction in nitric oxide production (P  .001). C-reactive protein
xposure inhibited translocation of protein kinase C compared with control (P .01).
urthermore, coincubation of C-reactive protein with endothelin-1 led to a synergistic
nhibition of protein kinase C translocation (P  .01). C-reactive protein exposure
educed protein kinase C activity by 40% compared with control (P  .02), although
oincubation with endothelin-1 had a synergistic reduction in activity (P  .02).
onclusions: Our results indicate that endothelin-1 exposure accentuated C-reactive
rotein’s impairment of endothelial nitric oxide production via synergistic inhibition
f protein kinase C translocation and activity. Our investigations suggest that
ndothelin-1 inhibition and protein kinase C stimulation may provide a novel
herapeutic strategy to improve vascular nitric oxide homeostasis and mitigate the
roatherosclerotic effects of C-reactive protein.
ndothelial dysfunction, an initiator of atherosclerosis, is manifested by al-
tered nitric oxide (NO) and endothelin-1 (ET-1) homeostasis. Impaired NO
release precedes the development of atherosclerosis and serves to reinforceascular pathology once established. ET-1 is one of the most potent endogenous
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1137
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CSPasoconstrictors1 and mediates a host of responses includ-
ng endothelial dysfunction, vasomotor contraction, leuko-
yte activation, and cellular proliferation.2,3 Diminished
roduction of NO and exaggerated release of ET-1 are
elieved to be key initiators of endothelial injury.3 Impaired
O homeostasis, a hallmark of endothelial dysfunction, not
nly reflects the degree of endothelial cell injury but also is
n active component of the atherosclerotic process. Re-
uced NO release results in heightened endothelial cell
hrombogenicity, loss of inflammatory cell inhibition, and
ltered vasomotor function. The deleterious effects of NO
mpairment finally culminate in the development of athero-
clerosis. Several investigators have demonstrated that ET-1
dversely affects endothelial function as well as outcomes
ollowing cardiac surgery.3-7 We have previously shown that
T-1 results in endothelial dysfunction following cardiac
ransplantation and antagonism with bosentan abrogated this
ffect.5 Recent evidence suggests that elevated levels of ET-1
ay impair NO production.8,9 However, the mechanisms by
hich elevated levels of ET-1 reduce NO production in endo-
helial cells have yet to be determined. Therefore, the injured
ndothelial cell has altered ET-1 and NO homeostasis, result-
ng in vasomotor impairment, immune activation, and
therosclerosis.
Abbreviations and Acronyms
CRP  C-reactive protein
eNOS  endothelial nitric oxide synthase
ET-1  endothelin-1
HSVEC human saphenous vein endothelial cell
M/C membrane-to-cytosolic (ratio)
NO  nitric oxide
PKC  protein kinase C
PMA  phorbol 12-myristate 13-acetate
Figure 1. A, Normal vascular NO homeostasis. B, Ch
facilitates the interactions between modified lipoprotei
cellular elements of the arterial wall, resulting in d
function and vasoconstriction. These same factors also
tion and vasomotor impairment. C, Our hypothesis that CRP
138 The Journal of Thoracic and Cardiovascular Surgery ● MaAccumulating evidence supports the concept that inflam-
ation plays a central role in the genesis of atherosclerosis
nd its complications.10,11 Chronic inflammation results
n endothelial dysfunction and facilitates the interactions
etween modified lipoproteins, monocyte-derived macro-
hages, T cells, and the normal cellular elements of the
rterial wall (Figure 1).10,11 This inflammatory process ul-
imately leads to the development and progression of ath-
rosclerosis.10,11 The inflammatory marker C-reactive pro-
ein (CRP) has been shown to predict myocardial infarction,
troke, and vascular death in a variety of settings.10-20 This
cute-phase reactant has also been demonstrated to predict
uture coronary events and also to portend the vulnerability
f an atherosclerotic lesion and the likelihood of plaque
upture.10-13,15,17-20 CRP augments the production of key
nflammatory cytokines such as interleukin-6 and directly
mpairs NO homeostasis.21 Verma and colleagues21 dem-
nstrated that CRP is not only a risk factor but also an active
layer in atherosclerosis by impairing NO production, re-
ulting in endothelial dysfunction with its associated nega-
ive consequences. The mechanisms underlying this impair-
ent in NO production remain unknown. Furthermore,
hether ET-1 enhances the potential proatherosclerotic ef-
ects of CRP remains unclear.
Protein kinase C (PKC) plays an important role in several
ignaling pathways and is a family of kinases composed of at
east 12 isozymes. Several investigators have demonstrated
hat ET-1 alters specific PKC isoform translocation and activ-
ty.22,23 We hypothesized that elevated levels of CRP and ET-1
mpair endothelial cell NO production via an isoform-specific
KC-mediated change in endothelial NO synthase (eNOS)
xpression and activity. We also propose that ET-1 accentuates
RP-induced injury and that bosentan, an ET-1 antagonist,
ay prevent both ET-1- and CRP-induced endothelial dys-
unction and restore normal vascular NO homeostasis.
inflammation results in endothelial dysfunction and
onocyte-derived macrophages, T cells, and the normal
sed NO production leading to impaired endothelial
ease ET-1 production, further promoting vasoconstric-ronic
ns, m
ecrea
incralters PKC activity leading to NO impairment.
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Paterials and Methods
ndothelial Cell Cultures
uman saphenous vein endothelial cells (HSVECs) were cultured
n 10-cm diameter dishes at 37°C and 5% CO2 in medium MCDB-
31 (VEC Technologies, Rensselaer, NY) containing 10% fetal
ovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin.
ells passaged 2 to 4 times and aged between 14 and 30 days from
he time of primary culture were used for this study. We examined
he effects of our interventions on eNOS expression, NO produc-
ion, isoform-specific PKC translocation, and PKC activity. Cells
ere treated with CRP (25 g/mL, Calbiochem, San Diego, Calif),
00 nM of ET-1 (Sigma, Oakville, Ontario, Canada), ET-1 
RP, or phosphate-buffered saline solution (control, n  12 per
roup) for 24 hours. ET-1 antagonism was achieved with the use
f bosentan 10 M (courtesy of Actelion Pharmaceuticals Ltd,
llschwil, Switzerland). We employed 2 PKC antagonists with
ifferent mechanisms of action, calphostin C (200 nM) and chel-
rythrine (1 M; Sigma). Chelerythrine inhibits the adenosine
riphosphate binding site, whereas calphostin C interferes with the
ipid cofactor-binding site of PKC. The PKC agonist phorbol
2-myristate 13-acetate (PMA; 10 nM; Sigma) was used to stim-
late PKC activity. The concentrations of these agents have been
reviously validated and published by our laboratory.24
O Production
ell culture supernatants were collected following treatment. NO
roduction was detected spectrophotometrically by measuring its
egradation products, nitrite and nitrate. Total nitrite was quanti-
ed after the reduction of all nitrates with nitrate reductase. After
he conversion of nitrate to nitrite, total nitrite was determined
pectrophotometrically at 540 m by using the Griess reaction.
otal nitrite concentration was calculated from a standard curve
nd expressed as mol/L per milligram protein. The amount of NO
roduced was normalized against total cellular protein and as-
essed using the Bradford method.25
rotein Expression
estern immunoblotting was performed using chemiluminescent
etection and protein-specific monoclonal antibodies for eNOS
BD Biosciences, Mississauga, Ontario, Canada). Samples were
eparated using sodium dodecylsulfate-polyacrylamide gel electro-
horesis. Gels were then transferred to polyvinylidene fluoride
embranes. Comparisons between groups were performed using
ensitometric analysis (BioRad, Hercules, Calif) corrected for
-actin expression.
KC Translocation/Activity
etermination of isoform-specific PKC translocation was performed
y analysis of cytosolic and membrane fractions of HSVEC to
alculate a membrane-to-cytosolic (M/C) ratio using Western blot
nalysis. Purity of the cytosolic and membrane fractions was
etermined by confirming the absence of membrane bound Ca-
TPase (cytosolic) or -actin (membrane). Our preliminary stud-
es indicated that only the , , , , and  PKC isoforms are
resent in this cell population. Therefore, each blot was stained
ith these isoform-specific antibodies. o
The Journal of ThoracicFor measurement of PKC activity, a commercially available
KC assay kit (Calbiochem) was used to determine protein-
djusted activity. Activity was determined colorimetrically at 490
m and is displayed as arbitrary units per mg of protein (U/mg).
tatistical Analysis
ll results are presented as means  SD. Statistical comparisons
ere made by analysis of variance followed by Dunn’s multiple
ontrast test to identify differences between various treatments.
xact P values are provided for each comparison. Statistical anal-
sis was performed with the SAS statistical software program
ersion 8.2 (SAS Institute, Inc, Cary, NC).
esults
RP and ET-1 Attenuate NO Release
reatment with CRP resulted in a 47% decrease in NO
roduction compared with control (Figure 1, A). Exposure
o ET-1 also reduced NO production (P  .001), although
oincubation with CRP led to a further 70% reduction in
O release (P  .001; Figure 2, A). Bosentan treatment was
ffective in attenuating the effects of ET-1 on NO produc-
ion; however, bosentan did not mitigate the effects of CRP.
SVEC exposed to bosentan alone demonstrated a significant
ncrease in NO production by approximately 20% (P .001).
ffect of PKC on Nitrate/Nitrite Production
xposure to the PKC inhibitors calphostin C and cheleryth-
ine significantly reduced NO release (P  .001; Table 1).
oincubation of ET-1 or CRP with our PKC inhibitors did
ot demonstrate any further reduction in NO production
Table 1). HSVEC treated with PMA demonstrated in-
reased NO release compared with control and significantly
brogated the effects of both CRP and ET-1 (Table 1).
RP and ET-1 effect on eNOS Protein Expression
xposure to CRP or ET-1 markedly downregulated eNOS
rotein expression by approximately 40% and 45% com-
ared with control (P  .004; Figure 2, B). Coincubation
emonstrated no added reduction in eNOS protein expres-
ion (Figure 2, B). Furthermore, PKC antagonism showed a
ignificant reduction in eNOS protein expression (Table 1).
o interactive effects were seen between PKC inhibitors
nd ET-1 or CRP (Table 1). PKC activation with PMA
esulted in a significant upregulation of eNOS protein ex-
ression compared with control and completely abolished
oth CRP- and ET-1-induced downregulation of eNOS ex-
ression (Table 1). Figure 1, B shows that bosentan treat-
ent prevented ET-1-induced downregulation, although it
ad no effect on CRP-induced reduction of eNOS expression.
KC Isoforms
e assessed our cell cultures for the presence of several
KC isoforms (, , , , , , , 	). We found the presence
f only , , , , and  isoforms in our HSVECs. No
and Cardiovascular Surgery ● Volume 133, Number 5 1139
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CSP
ignificant differences in PKC and PKC M/C ratios
translocation to the membrane) were seen between groups.
KC, , and  isoforms demonstrated significant changes
ollowing treatment (Figure 3, A, B, C).
CRP exposure resulted in no change in PKC transloca-
ion but increased PKC translocation (P  .02; Figure 3,
, B). The translocation of PKC was significantly reduced
ollowing CRP treatment (P  .01; Figure 3, C). ET-1
xposure resulted in increased PKC and PKC transloca-
ion compared with control and CRP (P  .05; Figure 3,
, B). Examination of the PKC isoform demonstrated that
T-1 significantly reduced the M/C ratio (suggesting inhi-
igure 2. A, NO production in HSVECs following treatment. The
resence of CRP and ET-1 significantly reduced NO production.
oincubation of CRP with ET-1 resulted in a greater decrease in NO
elease. Bosentan treatment prevented ET-1-induced impairment in
O release but did not prevent the effects of CRP. B, Quantitative
estern blot analysis following 24-hour exposure demonstrated that
RP, ET-1, and CRP  ET-1 exposure downregulated eNOS protein
xpression compared with control. Treatment of HSVEC with bosen-
an abrogated ET-1 inhibition of eNOS protein expression while
aving no effect on CRP-induced dowregulation.ition of translocation) compared with control (P  .01;
140 The Journal of Thoracic and Cardiovascular Surgery ● Maigure 3, C). Coincubation of CRP with ET resulted in a
reater increase in PKC translocation while reducing the
/C ratio for PKC (Figure 3, B, C).
PKC inhibition resulted in a significantly reduced M/C
atio for PKC and PKC in control and in treated cells
CRP, ET, and CRP  ET; Table 2). PKC translocation
as impaired following PKC inhibition only in the control
roups (P  .05). PKC activation resulted in significantly
reater translocation to the membrane of all PKC isoforms
n all our treatment groups except for PKC in the CRP 
T group (Table 2).
The effects of bosentan on HSVEC PKC translocation
ere significant. Bosentan demonstrated the ability to ab-
ogate both ET-1- and CRP-induced effects on PKC and
ttenuated CRP’s effect on PKC translocation (P  .05;
able 2). HSVEC exposed to bosentan with and without
T-1 demonstrated increased translocation of PKC com-
ared with control (P  .05). Bosentan minimally inhibited
RP-induced effects on PKC and abolished the effects of
T-1 when coincubated with CRP (Table 2).
KC Activity
etermination of PKC translocation does not necessarily cor-
elate with cellular PKC activity, and therefore we measured
irect overall PKC activity. Endothelial cells treated with CRP
r ET-1 displayed a significant reduction in PKC activity (P
01; Figure 4). A greater reduction was seen following coin-
ubation of CRP with ET-1 (Figure 4). Bosentan treatment
locked the ET-1-induced effect but also resulted in enhanced
KC activity (P  .05; Table 1). However, bosentan did not
brogate the CRP-induced effects. As expected, HSVEC
reated with calphostin C and chelerythrine demonstrated re-
uced PKC activity. No further effect of ET-1 on CRP was
een. PMA exposure increased PKC activity and abrogated
oth CRP- and ET-1-induced effects.
iscussion
RP and ET-1 are known to result in endothelial dysfunction
nd are risk factors for atherosclerosis.5,12,13,18-20 The normally
unctioning endothelium is maintained by the balance between
O and ET-1. Impairment in NO production and/or increased
elease of ET-1 are key initiators of endothelial dysfunction
nd injury.3 Given the importance of a normally functioning
ndothelium, we sought to determine the mechanisms by
hich CRP impairs NO bioavailability in isolated human en-
othelial cells. We further aimed to determine the effect of
T-1 exposure on CRP’s proatherosclerotic effects.
We have made the following observations outlined in
igure 5:
1. CRP attenuates NO production and downregulates
eNOS protein expression.
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P2. ET-1 accentuates the CRP-induced reduction in NO
release with no further downregulation of eNOS ex-
pression.
3. CRP appears to selectively stimulate PKC translo-
cation while inhibiting  translocation with a further
reduction in PKC translocation when coincubated
with ET-1.
4. CRP inhibits PKC activity with a further decrease
seen following ET-1 coincubation.
5. Bosentan can maintain cellular NO production fol-
lowing ET-1 exposure but does not prevent CRP-
induced impairment.
6. PKC inhibition leads to a severe reduction in cellular
NO production with no further reduction observed
with simultaneous exposure to CRP or ET-1.
7. PKC stimulation with PMA significantly increases
cellular NO production and is capable of completely
reversing the inhibitory effects of both CRP and ET-1
exposure.
ffect of CRP and ET-1 on NO Production
ur findings demonstrate that CRP has a deleterious effect on
O homeostasis in an vitro assessment of endothelial function.
T-1 also resulted in impaired NO production and aggravated
RP’s inhibitory effect on NO release. Prolonged exposure to
RP with the resultant impairment of NO production may
xplain its predictive value for determining atherosclerosis.
ur data confirm that CRP is an active player in the patho-
enesis of atherosclerosis by impairing NO homeostasis a
arker of endothelial dysfunction. Elevated ET-1 levels, as
een following ischemia-reperfusion, myocardial infarction, or
eart failure, may accelerate or enhance the atherosclerotic
urden in these patients.
Our results are consistent with the studies by Verma and
ABLE 1. Summary of NO production (M/mg) and eNOS
CON
O production (M/mg) (total nitrite)
No Tx 7.3 0.1
BOS 9.0 0.4*
Cal 1.3 0.3*
Chel 1.5 0.2*
PMA 11.9 0.4*
NOS expression (% control)
No Tx 100
BOS 98  10
Cal 58  5†
Chel 63  6†
PMA 129 10†
ON, Control; CRP, C-reactive protein; ET, endothelin-1; NO, nitric oxide; eN
al, calphostin C; Chel, chelerythrine; PMA, phorbol 12-myristate 13-aceta
P  .05 vs No Tx CRP and ET; P  .05 vs No Tx CRP  ET.olleagues21 and Dong and associates,8 which demonstrated b
The Journal of Thoracichat elevated CRP and ET-1 levels result in downregulation
f eNOS protein expression in endothelial cells. We dem-
nstrated that CRP-induced NO dysregulation was partly
aused by changes in eNOS protein expression. eNOS pro-
ein expression was downregulated following both CRP and
T-1 treatment. In contrast to NO production, no further
eduction in eNOS expression was seen with coincubation.
he greater impairment in NO production seen with coin-
ubation may be a result of decreased eNOS activity. De-
reased eNOS activity may be caused by changes in regu-
atory kinase activity such as PKC.
Our study demonstrated that NO production is regulated
y PKC. NO bioavailability is impaired following PKC
nhibition, and PKC activation led to NO release. Further
vidence that PKC is a player in both CRP- and ET-1-
nduced NO impairment is that concomitant exposure of
RP or ET-1 with PKC inhibition did not lead to a greater
eduction in NO bioavailability as would be anticipated if
hey acted in a PKC-independent fashion. The simultaneous
xposure of our endothelial cells to PMA and CRP or ET-1
esulted in increased NO production similar to exposure
o PMA alone. Our data support the hypothesis that CRP
nd ET-1 decrease NO production through PKC inhibition.
NOS protein expression was also regulated by PKC. We
ound that PKC antagonism downregulated eNOS protein
xpression, although PKC agonists upregulated eNOS pro-
ein expression. In addition, concomitant exposure of
SVECs to CRP or ET-1 with PMA resulted in upregula-
ion of eNOS to a level similar to PMA alone, further
emonstrating that CRP- and ET-1-induced alterations in
NOS expression is PKC dependent and is fully reversible
y direct PKC stimulation.
The differential roles of PKC on NO production have
in expression data (% control)
CRP ET CRP  ET
3.9  0.2* 4.3 0.2* 2.2 0.1*§
4.3  0.2*‡ 8.8 0.4* 4.0 0.1*‡
1.0  0.2*§ 1.1 0.2*§ 1.3 0.2*
1.1  0.5*§ 1.2 0.5*§ 1.4 0.2*
11.7 0.4*§ 10.8 0.3*§ 11.5 0.2*
59 3† 54  4† 53 6†
60  9†‡ 93  9 63  11†‡
58  3† 55  3† 54 4†
56  6† 60  8† 54 7†
122 10† 124 15† 123 8†
dothelial nitric oxide synthase; No Tx, no added treatment; BOS, bosentan;
 .001 vs No Tx CON; †P  .04 vs No Tx CON; ‡P  .05 vs BOS CON;prote
OS, en
te. *Peen observed in various animal models.26-28 Matsubara
and Cardiovascular Surgery ● Volume 133, Number 5 1141
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1
CSPnd colleagues26 in bovine aortic cells found that PKC
ctivation decreases NO production, although Partovian and
oworkers27 found that PKC activation increases NO for-
ation. Partovian and associates27 found that PKC acti-
ation increases eNOS activity in the vasculature, indicating
hat PKC regulation of eNOS is tissue and species depen-
ent. Therefore, depending on species and cell type, PKC
nhibition or activation can lead to NO impairment. In our
tudy, using human endothelial cells, we demonstrated that
KC inhibition, likely the lambda isoform, decreases eNOS
Figure 3. A, PKC translocation. Top, Western blot of PK
fractions (M) following treatment. Bottom, Quantitativ
ences were seen after CRP treatment, although ET-1 e
membrane compared with control. Coincubation of
translocation. B, PKC translocation. Top, Western b
membrane fractions (M) following treatment. Bottom,
PKC was significantly translocated to the membran
control. Coincubation demonstrated PKC translocatio
similar to ET-1 exposed cells. C, PKC translocation
fractions (C) and membrane fractions (M) following trea
translocation. Exposure of HSVECs to CRP and ET-1 cau
of CRP with ET-1 led to further decrease in PKC M/Crotein expression and NO production. n
142 The Journal of Thoracic and Cardiovascular Surgery ● Maffects of CRP and ET-1 on PKC Translocation
nd Activity
o determine which isoforms were involved in NO regula-
ion, we evaluated isoform-specific translocation. Our study
evealed that both CRP and ET-1 exposure resulted in
embrane translocation of the epsilon isoforms, although
he M/C ratio of the lambda isoform was reduced, suggest-
ng inhibited translocation. Coincubation of CRP with ET-1
ed to a greater increase in PKC translocation and further
educed PKC translocation. Because translocation does
xpression in the cytosolic fractions (C) and membrane
stern blot analysis of PKC translocation. No differ-
re resulted in a significant PKC translocation to the
with ET-1 resulted in a further increase in PKC
f PKC expression in the cytosolic fractions (C) and
titative Western blot analysis of PKC translocation.
lowing both CRP and ET-1 treatment compared with
t was significantly greater than that of CRP alone but
, Western blot of PKC expression in the cytosolic
t. Bottom, Quantitative Western blot analysis of PKC
significant lowering of PKCM/C ratio. Coincubation
o.C e
e We
xposu
CRP
lot o
Quan
e fol
n tha
. Top
tmen
sed a
ratiot always correlate with activity, we measured PKC activ-
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Pty in our cell cultures. We determined that cellular PKC
ctivity is reduced following both CRP and ET-1 exposure,
uggesting that inhibition of PKC activity is the likely mech-
nism by which CRP and ET-1 impairs NO production.
Our data revealed that ET-1 coincubated with CRP re-
ulted in the greatest reduction in PKC activity, which
orroborates the effect of ET-1 on CRP-induced NO im-
igure 4. HSVEC PKC activity. CRP and ET-1 caused a significant
ecrease in PKC activity compared with control with a further
ABLE 2. Summary of PKC translocation and activity (U/m
CON
KC M/C ratio
No Tx 1.17 0.10 1.21
BOS 1.18 0.13 1.15
Cal 0.68 0.15* 0.49
Chel 0.45 0.11* 0.41
PMA 2.87 0.23* 2.98
KC M/C ratio
No Tx 1.23 0.12 1.48
BOS 1.38 0.15 1.58
Cal 0.97 0.28† 0.96
Chel 0.98 0.13† 0.90
PMA 1.91 0.12† 1.97
KC M/C ratio
No Tx 0.72 0.05 0.36
BOS 1.05 0.03 0.54
Cal 0.36 0.21‡ 0.34
Chel 0.43 0.06‡ 0.38
PMA 2.07 0.19‡ 2.13
KC activity (U/mg)
No Tx 4.90 0.10 2.90
BOS 6.40 0.44* 3.40
Cal 0.91 0.21* 0.88
Chel 0.89 0.10* 0.86
PMA 9.40 0.16* 9.10
ON, Control; CRP, C-reactive protein; ET, endothelin-1; NO, nitric oxide; eN
al, calphostin C; Chel, chelerythrine; PMA, phorbol 12-myristate 13-aceta
01 vs No Tx CON; §PKC: P  .05 vs No Tx CRP and ET; PKC: P  .05
†PKC: P  .05 vs No Tx CRP  ET; ‡‡PKC: P  .05 vs No Tx CRP meduction seen following coincubation.
The Journal of Thoracicairment. The inhibition of eNOS protein expression was
imilar in all treatment groups; therefore, differences in NO
roduction were caused by changes in eNOS activity. We
peculate that eNOS activity is regulated by specific PKC
soforms. The results of our studies suggest that CRP and
T-1 reduces PKC translocation and overall PKC activity,
eading to decreased eNOS activity and impaired NO
roduction.
ET-1 has been extensively studied and found to typically
ncrease PKC translocation in various cell types.22,23,29-32
lugosz and colleagues22 demonstrated that ET-1 exposure
esults in PKC and PKC translocation in mesangial cells.
cNair and associates’31 data showed that PKC is acti-
ated by ET-1 exposure in coronary smooth muscle. Our
ndings are consistent with previous results demonstrating
KC and PKC translocation following ET-1 exposure.
ur observation that ET-1 reduces PKC translocation in
uman endothelial cells is a novel finding. We speculate that
nlike lower levels of ET-1, which normally results in G
rotein S activation leading to PKC translocation, higher
evels of ET-1 also activate G protein I, which leads to PKC
nhibition. Further studies are required to demonstrate the
ta
ET CRP  ET
.11 2.53 0.23* 3.34 0.25*¶
.16 1.27 0.15 1.33 0.06**
.12* 0.54 0.13* 0.45 0.10***
.08* 0.47 0.23* 0.43 0.14***
.21* 3.14 0.17* 3.54 0.20***
.05† 1.92 0.17† 1.97 0.08†§
.11† 1.33 0.10 1.62 0.17†
.23†§ 0.98 0.16†§ 1.06 0.10†††
.18†§ 0.93 0.07†§ 0.91 0.12†††
.14† 2.01 0.09† .99 0.03†
.07‡ 0.44 0.08‡ 0.13 0.04‡‡‡
.09‡ 1.09 0.07 0.52 0.08†‡§§
.07‡ 0.30 0.14‡ 0.14 0.23‡
.14‡ 0.34 0.17‡ 0.15 0.17‡
.15‡ 2.55 0.20‡ 2.22 0.21‡
.20* 3.90 0.10* 2.00 0.10*¶
.38* 5.90 0.58* 2.20 0.20*¶
.20* 0.88 0.39* 0.72 0.22*
.10* 0.88 0.18* 0.84 0.16*
.27* 9.00 0.38* 8.80 0.32*
dothelial nitric oxide synthase; No Tx, no added treatment; BOS, bosentan;
KC: P  .01 vs No Tx CON; †PKC: P  .02 vs No Tx CON; ‡PKC: P 
P; ¶PKC: P  .05 vs No Tx CRP and ET; **PKC: P  .05 vs CRP  ET;
§PKC: P  .05 vs No Tx CRP  ET.g) da
CRP
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
OS, en
te. *P
vs CRechanisms behind ET-1-induced PKC inhibition.
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CSPffects of ET-1 Antagonism
ur study also sought to determine whether endothelin
lockade with bosentan can prevent ET-1- and CRP-
nduced impairment in NO homeostasis. The beneficial ef-
ects of ET-1 antagonism have previously been observed
ollowing ischemia and reperfusion and in cardiac trans-
lantation.5,33-35 We have previously demonstrated that
osentan enhances endothelial protection during cardiac
llograft storage.5 In atherosclerotic mice, Barton and co-
orkers35 also showed that ET-1 blockade restores NO-
ediated endothelial function. Li and associates36 have
emonstrated that ET-1 antagonism may attenuate CRP-
nduced endothelial dysfunction. They showed that ET-1
lockade reduces CRP-induced upregulation of lectinlike
xidized low-density lipoprotein receptor-1.36 Our study
xamined the effect of ET-1 antagonism on CRP-induced
mpairment of NO homeostasis. However, ET-1 antagonism
oes not appear to preserve NO production following CRP
xposure. When bosentan was given to the CRP  ET
roups, the incremental deleterious effect of ET-1 on NO
roduction was eliminated. In our experiments, bosentan
ailed to inhibit CRP’s effect on eNOS expression; however,
t completely abrogated ET-1-induced downregulation.
osentan exposure resulted in increased PKC activity as
ell as greater PKC translocation compared with CRP,
T-1, and control. Bosentan’s effects seem to further sup-
ort the position that PKC is the key isoform involved in
O regulation. In support of this conclusion is the fact that
osentan results in increased NO production although only
ncreases PKC translocation and PKC activity.
The present study demonstrates a potential mechanism
ehind CRP- and ET-1-induced injury and suggests possible
herapeutic strategies. Although bosentan treatment was
eneficial in reducing ET-1 injury as well as eliminating the
dded effect of ET-1 on CRP’s proatherosclerotic effect, it
Figure 5. A, B, Human endothelial cell exposed to CR
PKC activity and translocation leading to eNOS down
further reduces endothelial cell NO release by enhancas unable to block CRP-induced endothelial cell injury
144 The Journal of Thoracic and Cardiovascular Surgery ● Massessed by decreased NO production. Bosentan may be
eneficial in those patients who have both elevated CRP and
T-1 levels, such as patients having cardiac transplant or
eart failure. Caution must be taken with bosentan, as we
reviously found that administration of bosentan can result
n severe vasodilation and hypotension, rendering its clini-
al use problematic. Similarly, despite widespread evidence
hat ET-1 levels are elevated in congestive heart failure,
arge randomized clinical trials such as The ENABLE trials
Endothelin Antagonist Bosentan for Lowering Cardiac
vents in Heart Failure) also demonstrated a higher rate of
udden death, potentially due to hypotension-related ar-
hythmias. Therefore, care must be taken with the use of
T-1 antagonism, especially in patients with heart failure.
ence, determining the mechanism of benefit for ET-1
lockade may permit the development of novel targeted
herapies without the side effects associated with a nonse-
ective antagonist. The effects of CRP are not mitigated by
ndothelin antagonism alone. We suggest that PKC modu-
ation may be the optimal strategy to reduce the atheroscle-
otic burden in patients with elevated acute phase reactants
uch as CRP and ET-1. The results of these investigations
ave obvious clinical implications for patients with acute
oronary syndrome, post–coronary artery bypass graft pa-
ency, and transplant vasculopathy. Further studies are re-
uired to assess the potential benefits of PKC modulation in
reventing endothelial dysfunction.
eferences
1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M,
Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by
vascular endothelial cells. Nature. 1988;332:411-5.
2. Luscher TF. Endothelin. Key to coronary vasospasm? Circulation.
1991;83:701-3.
3. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, bio-
ET-1 results in decreased NO production by reducing
lation. C, The concomitant exposure of ET-1 with CRP
KC inhibition and increased eNOS downregulation.P or
regu
ing Pchemistry, pharmacology, physiology, and pathophysiology. Pharma-
col Rev. 1994;46:325-415.
y 2007
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
D
D
c
f
e
u
a
q
q
a
o
b
v
n
r
t
b
f
r
w
l
Ramzy et al Cardiopulmonary Support and Physiology
CS
P4. Berkenboom G, Giot C, Unger P, Vachiery JL, Antoine M, LeClerc
JL. Plasma endothelin and early coronary endothelial dysfunction in
recipients of a cardiac transplant. Am Heart J. 1995;129:1178-84.
5. Fedak PW, Rao V, Verma S, Ramzy D, Tumiati L, Miriuka S, et al.
Combined endothelial and myocardial protection by endothelin antag-
onism enhances transplant allograft preservation. J Thorac Cardiovasc
Surg. 2005;129:407-15.
6. Vassalli G, Gallino A. Endothelial dysfunction and accelerated coro-
nary artery disease in cardiac transplant recipients. Microcirculation
Working Group, European Society of Cardiology. Eur Heart J. 1997;
18:1712-7.
7. Weis M, Wildhirt SM, Schulze C, Rieder G, Wilbert-Lampen U, Wolf
WP, et al. Endothelin in coronary endothelial dysfunction early after
human heart transplantation. J Heart Lung Transplant. 1999;18:1071-9.
8. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1
enhances oxidative stress, cell proliferation and reduces apoptosis in
human umbilical vein endothelial cells: role of ET(B) receptor,
NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323-33.
9. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS
expression and activity through ETA receptor-mediated generation of
hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol. 2005;288:
L480-7.
0. Ross R. The pathogenesis of atherosclerosis: a perspective for the
1990s. Nature. 1993;362:801-9.
1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med.
1999;340:115-26.
2. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and
promising marker of coronary heart disease. Clin Chem. 2001;47:403-11.
3. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic
atherosclerosis: a comparison of C-reactive protein, fibrinogen, homo-
cysteine, lipoprotein(a), and standard cholesterol screening as predic-
tors of peripheral arterial disease. JAMA. 2001;285:2481-5.
4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive
protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
JAMA. 2001;286:327-34.
5. Blake GJ, Ridker PM. Inflammatory mechanisms in atherosclerosis:
from laboratory evidence to clinical application. Ital Heart J. 2001;2:
796-800.
6. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive
protein specific for vascular disease in women? Ann Intern Med.
2002;136:529-33.
7. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study
of C-reactive protein, homocysteine, and plasma lipid levels as pre-
dictors of sudden cardiac death. Circulation. 2002;105:2595-9.
8. Blake GJ, Ridker PM. C-reactive protein and other inflammatory
risk markers in acute coronary syndromes. J Am Coll Cardiol.
2003;41(4 suppl S):37S-42S.
9. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coro-
nary risk. Cardiol Clin. 2003;21:315-25.
0. Libby P, Ridker PM. Inflammation and atherosclerosis: role of
C-reactive protein in risk assessment. Am J Med. 2004;116(suppl
6A):9S-16S.
1. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV,
et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric
oxide production and inhibits angiogenesis. Circulation. 2002;106:
913-9.
2. Dlugosz JA, Munk S, Zhou X, Whiteside CI. Endothelin-1-induced
mesangial cell contraction involves activation of protein kinase C-
alpha, -delta, and -epsilon. Am J Physiol. 1998;275(3 Pt 2):F423-32.
3. Park WS, Ko EA, Han J, Kim N, Earm YE. Endothelin-1 acts via
protein kinase C to block KATP channels in rabbit coronary and
pulmonary arterial smooth muscle cells. J Cardiovasc Pharmacol.
2005;45:99-108.
4. Ikonomidis JS, Shirai T, Weisel RD, Derylo B, Rao V, Whiteside CI,
et al. Preconditioning cultured human pediatric myocytes requires
adenosine and protein kinase C. Am J Physiol. 1997;272(3 Pt 2):
H1220-30.
5. Bradford MM. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem. 1976;72:248-54. f
The Journal of Thoracic6. Matsubara M, Hayashi N, Jing T, Titani K. Regulation of endothelial
nitric oxide synthase by protein kinase C. J Biochem (Tokyo). 2003;
133:773-81.
7. Partovian C, Zhuang Z, Moodie K, Lin M, Ouchi N, Sessa WC, et al.
PKCalpha activates eNOS and increases arterial blood flow in vivo.
Circ Res. 2005;97:482-7.
8. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way
KJ, et al. Activation of vascular protein kinase C-beta inhibits Akt-
dependent endothelial nitric oxide synthase function in obesity-
associated insulin resistance. Diabetes. 2006;55:691-8.
9. Lee TS, Chao T, Hu KQ, King GL. Endothelin stimulates a sustained
1,2-diacylglycerol increase and protein kinase C activation in bovine
aortic smooth muscle cells. Biochem Biophys Res Commun. 1989;162:
381-6.
0. Lee TS, Hu KQ, Chao T, King GL. Characterization of endothelin
receptors and effects of endothelin on diacylglycerol and protein
kinase C in retinal capillary pericytes. Diabetes. 1989;38:1643-6.
1. McNair LL, Salamanca DA, Khalil RA. Endothelin-1 promotes Ca2
antagonist-insensitive coronary smooth muscle contraction via activa-
tion of epsilon-protein kinase C. Hypertension. 2004;43:897-904.
2. Robin P, Boulven I, Desmyter C, Harbon S, Leiber D. ET-1 stimulates
ERK signaling pathway through sequential activation of PKC and Src
in rat myometrial cells. Am J Physiol Cell Physiol. 2002;283:C251-60.
3. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al.
Endothelin antagonism and interleukin-6 inhibition attenuate the
proatherogenic effects of C-reactive protein. Circulation. 2002;105:
1890-6.
4. Gonon AT, Erbas D, Broijersen A, Valen G, Pernow J. Nitric oxide
mediates protective effect of endothelin receptor antagonism during
myocardial ischemia and reperfusion. Am J Physiol Heart Circ
Physiol. 2004;286:H1767-74.
5. Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Munter K,
Luscher TF. Endothelin ETA receptor blockade restores NO-mediated
endothelial function and inhibits atherosclerosis in apolipoprotein E-
deficient mice. Proc Natl Acad Sci U S A. 1998;95:14367-72.
6. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein
enhances LOX-1 expression in human aortic endothelial cells: rele-
vance of LOX-1 to C-reactive protein-induced endothelial dysfunc-
tion. Circ Res. 2004;95:877-83.
iscussion
r Y. Joseph Woo (Philadelphia, Pa). The authors should be
ongratulated on a great body of work and, as usual, great graphics
rom Toronto. Are venous endothelial cells the same as arterial
ndothelial cells, and are they an adequate surrogate if you are
sing this as a model for allograft vasculopathy and other sorts of
rterial problems?
Dr Danny Ramzy (Toronto, Canada). Thank you for the
uestion. We have actually performed experiments looking at that
uestion. Between human saphenous vein endothelial cells, human
ortic endothelial cells, and human coronary endothelial cells,
nce you pass the first passage, and all experiments are performed
eyond P1, they all behave the same way as ET-1 and other
asoconstrictors and soluble factors. So in terms of using saphe-
ous vein versus aortic cells, the experiments will yield the same
esults.
Dr Mark J. Krasna (Baltimore, Md). Dr Ramzy, could you
ell us a little bit about bosentan? It sounds very exciting. Has it
een used clinically in your group in any other arena yet?
Dr Ramzy. It has been used clinically. It is approved primarily
or primary pulmonary hypertension. It reduces mortality and does
educe pulmonary arterial pressures. It has been used in patients
ith heart failure, with a few of the studies actually showing harm,
ikely due to its induction of hypotension. The patient with heart
ailure died from sudden death, likely from arrhythmia due to
and Cardiovascular Surgery ● Volume 133, Number 5 1145
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CSPypotension. So other than in that setting, it has been used safely
n patients who can be monitored closely or who have adequate
lood pressure. The main problem is the blood pressure.
Dr Krasna. Have either of those groups had any relationship
etween atherosclerosis and bad outcomes and use of bosentan?
Dr. Ramzy. It has been looked at mostly in allograft vascu-
opathy in terms of as a surrogate of atherosclerosis, and it does
educe the burden in terms of amount of disease and the degree of
tenosis.
Dr John G. Byrne (Nashville, Tenn). What do you think are
he principal clinical applications of these findings?
D. Ramzy. The clinical applications are severalfold. In terms of
therosclerosis, the reduction of CRP and ET-1 does reduce both
he atherosclerotic burden and outcomes such as myocardial in-
arction. From our results in terms of protein kinase C, we could
ore specifically target the mechanisms by which CRP results in
therosclerosis and endothelial dysfunction, both in the transplant
etting and in atherosclerosis, and especially following transplan-
ation where there is a high degree of vein restenosis, which, if we146 The Journal of Thoracic and Cardiovascular Surgery ● Mand CRP with bosentan or targeted therapy, we could reduce graft
estenosis and improve survival and quality of life.
Dr Byrne. Are you talking about a vein graft?
Dr Ramzy. Vein graft.
Dr Turki Albacker (Montreal, Canada). Just for my curiosity,
or the clinical application of this study, what do you think about
he level of CRP in a patient posttransplant and do you think it is
igh enough to cause atherosclerosis so you can target it with your
herapy? Thanks.
Dr Ramzy. There are several studies looking at CRP posttrans-
lant. There are a group of patients who do have elevated levels of
RP, so any level above 3 g/mL does result in poor outcome.
here is actually a recent study that shows any levels above 1.06
g/mL result in poor outcome. So a slight increase in CRP is able
o result in worse outcomes in terms of earlier development of
llograft vasculopathy and worse disease, and it has been also
hown if you reduce this level, there is a trend toward improve-
ent. Of course, the concentration we used was 25 g, which is in
he intermediate level. We have done studies previous to that. Any
an modulate basically soluble inflammatory markers like ET-1 level above 3 g/mL does result in endothelial dysfunction.
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